Study Number:	C12013-01
Study Sex:	Male
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.7.5
Stat Version:	2.0.1A

Study Number: C12013-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 2-(5-Chloro-2H-benzotriazol-2-yl)-4,6-bis(1,1-dimethylethyl)phenol
CAS Number: 3864-99-1

Date Report Requested: 04/20/2026
Time Report Requested: 11:52:00
Lab: Battelle

Male

		Treatment Groups (mg/kg)				
	Phase Day	**0**	**30**	**100**	**300**	**1000**
Urea Nitrogen (mg/dL)	SD 14	19.4 ± 0.9 (5)	21.2 ± 0.4 (5)	20.0 ± 1.3 (5)	20.8 ± 1.0 (5)	19.8 ± 1.0 (5)
Percent of Control			109.3	103.1	107.2	102.1
Creatinine (mg/dL)	SD 14	0.40 ± 0.00 (5)	0.36 ± 0.02 (5)	0.40 ± 0.00 (5)	0.36 ± 0.02 (5)	0.38 ± 0.02 (5)
Percent of Control			90.0	100.0	90.0	95.0
Glucose (mg/dL)	SD 14	142.6 ± 11.2 (5)	134.6 ± 5.6 (5)	136.4 ± 11.8 (5)	134.0 ± 10.5 (5)	135.6 ± 9.0 (5)
Percent of Control			94.4	95.7	94.0	95.1
Total Protein (g/dL)	SD 14	6.88 ± 0.13 (5)	6.52 ± 0.15 (5)	6.28 ± 0.14 (5) *	6.38 ± 0.16 (5)	6.42 ± 0.12 (5)
Percent of Control			94.8	91.3	92.7	93.3
Globulin (g/dL)	SD 14	2.52 ± 0.14 (5) **	1.46 ± 0.09 (5) **	1.32 ± 0.04 (5) **	1.34 ± 0.08 (5) **	1.38 ± 0.07 (5) **
Percent of Control			57.9	52.4	53.2	54.8
A/G Ratio	SD 14	1.75 ± 0.10 (5) **	3.51 ± 0.18 (5) **	3.77 ± 0.11 (5) **	3.81 ± 0.22 (5) **	3.69 ± 0.20 (5) **
Percent of Control			200.2	214.9	217.5	210.7
Albumin (g/dL)	SD 14	4.36 ± 0.05 (5) *	5.06 ± 0.07 (5) *	4.96 ± 0.12 (5)	5.04 ± 0.10 (5) *	5.04 ± 0.09 (5) *
Percent of Control			116.1	113.8	115.6	115.6
Cholesterol (mg/dL)	SD 14	121.6 ± 10.1 (5) *	91.6 ± 4.1 (5)	74.4 ± 4.5 (5) **	91.6 ± 5.0 (5)	86.0 ± 3.3 (5)
Percent of Control			75.3	61.2	75.3	70.7
Triglyceride (mg/dL)	SD 14	103.6 ± 8.2 (5)	93.8 ± 9.1 (5)	98.8 ± 5.8 (5)	95.4 ± 9.6 (5)	91.8 ± 7.7 (5)
Percent of Control			90.5	95.4	92.1	88.6
Alanine Aminotransferase (IU/L)	SD 14	65.2 ± 3.6 (5)	73.0 ± 4.2 (5)	76.2 ± 6.5 (5)	76.0 ± 3.9 (5)	68.4 ± 4.8 (5)
Percent of Control			112.0	116.9	116.6	104.9
Alkaline Phosphatase (IU/L)	SD 14	215.2 ± 11.5 (5) **	318.2 ± 8.3 (5) **	386.6 ± 25.1 (5) **	352.6 ± 24.6 (5) **	364.4 ± 12.9 (5) **
Percent of Control			147.9	179.6	163.8	169.3

Study Number: C12013-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 2-(5-Chloro-2H-benzotriazol-2-yl)-4,6-bis(1,1-dimethylethyl)phenol
CAS Number: 3864-99-1

Date Report Requested: 04/20/2026
Time Report Requested: 11:52:00
Lab: Battelle

Male

		Treatment Groups (mg/kg)				
	Phase Day	**0**	**30**	**100**	**300**	**1000**
Creatine Kinase (IU/L)	SD 14	180.4 ± 20.8 (5)	129.2 ± 16.7 (5)	171.0 ± 20.5 (4)	153.2 ± 21.8 (5)	155.5 ± 27.0 (4)
Percent of Control			71.6	94.8	84.9	86.2
Sorbitol Dehydrogenase (IU/L)	SD 14	9.8 ± 0.6 (5)	10.6 ± 0.6 (5)	13.0 ± 2.1 (5)	11.2 ± 0.8 (5)	12.0 ± 1.2 (5)
Percent of Control			107.5	132.2	114.1	122.6
Bile salt/acids (umol/L)	SD 14	25.0 ± 6.9 (5)	66.6 ± 7.1 (5) *	79.0 ± 11.9 (5) *	24.4 ± 5.0 (5)	43.8 ± 9.5 (5)
Percent of Control			266.4	316.0	97.6	175.2

LEGEND

Values given as mean ± SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD = Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at p <= 0.05

** Statistically significant at p <= 0.01

SEM = Standard Error of the Mean

Clinical chemistry data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis.

** END OF REPORT **